IREN
IREN Limited
There isn't enough reported data to score IREN yet.
NEWT
NewtekOne, Inc.
NEWT's fundamentals are mixed: revenue grew only 1.5%, but earnings per share fell 16%. At 5.5x earnings, it's trading below its usual 7.2x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
NEWT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
NEWT's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like NEWT.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
NEWT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 5.2x | $10.44 | — |
| Cheap | 5.5x | $10.25 | -1.8% |
| Current | 5.6x | $10.44 | — |
| Fair | 7.1x | $13.41 | +28% |
| Expensive | 10x | $19.07 | +83% |
Historical ranges are pointers, not guarantees.
NEWT's PE is in its cheap range at 5.5x. On analysts' estimates for next year's earnings, today's price would be 5.2x.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NEWT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NEWT's profitability to weaken, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
NEWT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +7.3% |
| Q3 2026 | $1.88 | -16% |
| Q2 2026 | $2.21 | +9.4% |
| Q1 2026 | $2.26 | +17% |
| Q4 2025 | $2.18 | +11% |
| Q3 2025 | $2.24 | +32% |
| Q2 2025 | $2.02 | +24% |
| Q1 2025 | $1.93 | +32% |
| Q4 2024 | $1.96 | +27% |
NEWT has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
NEWT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $71.8M | -4.2% |
| Q2 2026 | $75.1M | +7% |
| Q1 2026 | $71M | +7% |
| Q4 2025 | $73.3M | -2.7% |
| Q3 2025 | $74.9M | +19% |
| Q2 2025 | $70.2M | +15% |
| Q1 2025 | $66.3M | +14% |
| Q4 2024 | $75.4M | +42% |
NEWT's revenue has held roughly level: $72M last quarter, down 4.2% from the same quarter a year ago.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN has the edge over NEWT on cash flow, with more consistent year-over-year improvement.
NEWT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$152.4M | +$14.9M |
| Q2 2026 | -$163.3M | +$36.6M |
| Q1 2026 | -$257.5M | -$196.8M |
| Q4 2025 | -$151.4M | -$59.8M |
| Q3 2025 | -$167.3M | -$141.4M |
| Q2 2025 | -$199.9M | -7108% |
| Q1 2025 | -$60.7M | -$22M |
| Q4 2024 | -$91.7M | -$39M |
NEWT's free cash flow was −$725M over the past year, against −$520M the year before. Free cash flow isn't a meaningful measure for financial services companies like NEWT.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
NEWT Net Leverage
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
NEWT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 2.7 | Oversold |
NEWT's weekly RSI is 36 (neutral) and its Stochastic is 3 (oversold).
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
NEWT PE vs Financial Services Sector
| Metric | NEWT | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 13x | 57% below |
| PE % | 19 | 63 | 44 pts below |
NEWT is trading at 5.5x earnings, a 57% discount to the Financial Services sector's median of 13x.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has the edge over NEWT on trend strength, trading above more of its moving averages.
NEWT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 4.7% below |
| 20 week MA | $12.4 | 16% below |
| 50 week MA | $12.6 | 17% below |
| 100 week MA | $12.1 | 14% below |
| 200 week MA | $13.0 | 19% below |
NEWT is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.
NEWT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.7 | $18.2 | -20% |
| 2021 | $18.2 | $27.9 | +54% |
| 2022 | $27.9 | $16.7 | -40% |
| 2023 | $16.7 | $13.8 | -17% |
| 2024 | $13.8 | $13.0 | -5.7% |
| 2025 | $13.0 | $11.5 | -12% |
| 2026 YTD | $11.5 | $10.4 | -9.1% |
NEWT has the edge over IREN on returns for 2026, with the stronger performance.